<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01031186</url>
  </required_header>
  <id_info>
    <org_study_id>113324</org_study_id>
    <nct_id>NCT01031186</nct_id>
  </id_info>
  <brief_title>First Time in Human Study</brief_title>
  <acronym>FTIM</acronym>
  <official_title>A First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK356278 (PDE4 Inhibitor) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and pharmacokinetics of GSK356278 in male&#xD;
      volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety, tolerability and pharmacokinetics of single ascending doses of&#xD;
      GSK356278 and may assess the effect of food on GSK356278 pharmacokinetics. They study will&#xD;
      assess the compound's effect on nausea, emesis and alertness. Close monitoring of&#xD;
      cardiovascular parameters will be included.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 23, 2009</start_date>
  <completion_date type="Actual">April 7, 2010</completion_date>
  <primary_completion_date type="Actual">April 7, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess safety and tolerability of single escalating oral doses of GSK356278 in healthy male volunteers</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the pharmacokinetics of single escalating doses of GSK356278 in healthy male volunteers</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Depressive Disorder and Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>Cohort 1, Session 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 1, the subjects will be administered 0.5 mg GSK356278 and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Session 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 2, the subjects will be administered GSK356278 (0.5 mg and 1.5 mg) and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Session 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 3, the subjects will be administered GSK356278 (1.5 mg and 4 mg) and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Session 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 4, the subjects will be administered GSK356278 (4 mg and 8 mg) and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Session 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 5, the subjects will be administered GSK356278 8 mg and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Session 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 1, the subjects will be administered 8 mg GSK356278 and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Session 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 2, the subjects will be administered GSK356278 (8 mg and 16 mg) and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Session 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 3, the subjects will be administered GSK356278 (16 mg and 30 mg) and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Session 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 4, the subjects will be administered GSK356278 (30 mg and 50 mg) and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Session 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 5, the subjects will be administered GSK356278 50 mg and placebo in a fasted state. The subjects will undergo food assessment session in Session 5 incase they experience nausea. In food assessment session, the subjects will receive a dose of GSK356278 after a standard breakfast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK356278</intervention_name>
    <description>GSK356278</description>
    <arm_group_label>Cohort 1, Session 1</arm_group_label>
    <arm_group_label>Cohort 1, Session 2</arm_group_label>
    <arm_group_label>Cohort 1, Session 3</arm_group_label>
    <arm_group_label>Cohort 1, Session 4</arm_group_label>
    <arm_group_label>Cohort 1, Session 5</arm_group_label>
    <arm_group_label>Cohort 2, Session 1</arm_group_label>
    <arm_group_label>Cohort 2, Session 2</arm_group_label>
    <arm_group_label>Cohort 2, Session 3</arm_group_label>
    <arm_group_label>Cohort 2, Session 4</arm_group_label>
    <arm_group_label>Cohort 2, Session 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>PLACEBO</description>
    <arm_group_label>Cohort 1, Session 1</arm_group_label>
    <arm_group_label>Cohort 1, Session 2</arm_group_label>
    <arm_group_label>Cohort 1, Session 3</arm_group_label>
    <arm_group_label>Cohort 1, Session 4</arm_group_label>
    <arm_group_label>Cohort 1, Session 5</arm_group_label>
    <arm_group_label>Cohort 2, Session 1</arm_group_label>
    <arm_group_label>Cohort 2, Session 2</arm_group_label>
    <arm_group_label>Cohort 2, Session 3</arm_group_label>
    <arm_group_label>Cohort 2, Session 4</arm_group_label>
    <arm_group_label>Cohort 2, Session 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AST, ALT, alkaline phosphate and bilirubin less than or equal to 1.5 times upper limit&#xD;
             of normal.&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician based on a medical&#xD;
             evaluation including medical history, physical examination, laboratory tests and&#xD;
             cardiac monitoring.&#xD;
&#xD;
          -  Males aged between 18 and 65 years inclusive at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          -  Males must agree to appropriate forms of contraception from administration of first&#xD;
             dose through to 3 months after taking the final dose.&#xD;
&#xD;
          -  Body weight greater than or equal to 50 kg and BMI within the range of 18-29.9 m2&#xD;
             (inclusive)&#xD;
&#xD;
          -  Capable of giving written informed consent.&#xD;
&#xD;
          -  QTcB or QTcF less than 450 msec&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A positive pre-study Hep B or positive Hep C result within 3 months of screening.&#xD;
&#xD;
          -  Current or chronic history of liver disease or known hepatic or biliary abnormalities&#xD;
&#xD;
          -  A positive pre-study alcohol and drug screen&#xD;
&#xD;
          -  A positive test for HIV antibody.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as an&#xD;
             average weekly intake of greater than 21 units or average daily intake of greater than&#xD;
             3 units&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received investigational&#xD;
             product within the time period of 30 days prior to first dosing day (or 5 half-lives&#xD;
             or twice the duration of the biological effect of the drug, whichever is longer)&#xD;
&#xD;
          -  Exposure to more than 4 new chemical entities in the last 12 months prior to the first&#xD;
             dosing day&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs including vitamins, herbal and dietary&#xD;
             supplements within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5&#xD;
             half-lives (whichever is longer) prior to the first dose unless in the opinion of the&#xD;
             investigator and medical monitor the medication will not interfere with the study&#xD;
             procedures or compromise subject safety.&#xD;
&#xD;
          -  History of sensitivity to any of the study medication or history of drug or other&#xD;
             allergy that in the opinion of the investigator or medical monitor contraindicates&#xD;
             their participation.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 ml within a 56 day period.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures in the protocol.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated.&#xD;
&#xD;
          -  Subjects who have asthma or a history of asthma.&#xD;
&#xD;
          -  Urinary cotinine levels indicative of smoking or history of regular use of tobacco or&#xD;
             nicotine containing products within 6 months prior to screening.&#xD;
&#xD;
          -  Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or&#xD;
             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior&#xD;
             to the first dose.&#xD;
&#xD;
          -  History of any significant psychiatric illness.&#xD;
&#xD;
          -  Any history of suicidal behaviour or any suicidal ideation of type 4 or 5 on the&#xD;
             Columbia Suicide Severity Rating Scale in the last 6 months.&#xD;
&#xD;
          -  History of presence of clinically significant cardiac arrhythmias or other clinically&#xD;
             significant cardiac disease.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>November 5, 2009</study_first_submitted>
  <study_first_submitted_qc>December 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2009</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy male volunteers</keyword>
  <keyword>GSK356278</keyword>
  <keyword>first time in man</keyword>
  <keyword>major depressive disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113324</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113324</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113324</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113324</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113324</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113324</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113324</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

